Richard D
National Blood Transfusion Center, Paris-Orsay, France.
J Virol Methods. 1987 Aug;17(1-2):105-17. doi: 10.1016/0166-0934(87)90073-5.
Non-A, non-B hepatitis represents an important problem for public health throughout the world. For several years, Transfusion Centers have been looking into improvements for more efficiently preventing post-transfusion non-A, non-B hepatitis. The viruses involved in such a pathology have not yet been isolated and no specific marker is available for direct screening and prevention. Surrogate markers, alanine aminotransferase and anti-HBc antibody have been evaluated by different teams, however, for this purpose. Fifty or 60% of transfusion-related non-A, non-B hepatitis could be prevented thanks to these markers, but such a strategy would induce a high loss of blood products. Therefore, a compromise must be found between quality objectives and economical costs, generated by this procedure. The social and financial costs of chronic hepatitis for the public health would be balanced by costs involved in such a screening policy and therefore Transfusion Centers should probably initiate this quality improvement using one or both tests in the near future.
非甲非乙型肝炎是全球公共卫生领域的一个重要问题。多年来，输血中心一直在探索改进措施，以更有效地预防输血后非甲非乙型肝炎。导致这种病理状况的病毒尚未分离出来，也没有可用于直接筛查和预防的特异性标志物。然而，不同团队已针对此目的对替代标志物谷丙转氨酶和抗-HBc抗体进行了评估。借助这些标志物，50%或60%与输血相关的非甲非乙型肝炎能够得到预防，但这样的策略会导致血液制品大量损失。因此，必须在该程序产生的质量目标和经济成本之间找到平衡。慢性肝炎给公共卫生带来的社会和经济成本将由这种筛查政策所涉及的成本来平衡，所以输血中心可能应在不久的将来采用一项或两项检测来启动这种质量改进。
